Acumen Pharmaceuticals, Inc. Form 8-K Filing

Acumen Pharmaceuticals, Inc. announced on March 13, 2026, that it entered into a Securities Purchase Agreement with certain institutional accredited investors for a private placement. The company agreed to sell 10,833,331 shares of its common stock at $3.30 per share, expecting to raise approximately $35.75 million before fees. The net proceeds will primarily support the Enhanced Brain Delivery (EBD) program and general corporate purposes. The private placement is expected to close on March 16, 2026, subject to customary closing conditions. The shares were offered under an exemption from registration pursuant to Section 4(a)(2) of the Securities Act. Concurrently, the company entered into a Registration Rights Agreement with the investors, obligating the company to file a resale registration statement with the SEC. The company also announced preclinical data supporting its EBD program via a press release and an updated corporate presentation on March 16, 2026.